H.C. Wainwright Downgrades Proteon Therapeutics Inc to Neutral with Price Target $3

Brokerage firm H.C. Wainwright Downgrades its rating on Proteon Therapeutics Inc(PRTO). As per the latest information, H.C. Wainwright Lowers the price target to $3 per share from a prior target of $18. The shares have been rated Neutral. Previously, the analysts had a Buy rating on the shares. The rating by the stock financial advisor at H.C. Wainwright was issued on Mar 17, 2017 in a research report to their Investors and Clients.

Proteon Therapeutics Inc (PRTO) remained unchanged at the close of Wednesday session. Even as the volume increased to 32,077 ,the shares failed to make any impression and ended at 0 points or 0.00% at $1.55. The trading session commenced at $1.6 and the stock hit a high of $1.6 and touched $1.55 at the lower end. Considering that the stock pared all of the losses, it can be said as a positive sign. The share price has a 52-week high of $11.63 and the 52-week low is $1.4. The company has a market cap of $26 M and has approximately 1,66,03,559 outstanding shares.

Proteon Therapeutics Inc(PRTO) last announced its earnings results on Mar 16, 2017 for Fiscal Year 2016 and Q4.Earnings per share were $-0.41. Analysts had estimated an EPS of $-0.46.

Several Insider Transactions has been reported to the SEC. On Jun 7, 2016, George Arthur Eldridge, (CFO) purchased 4,000 shares at $5.77 per share price.Also, On Jan 5, 2016, Timothy P Noyes (President and CEO) sold 5,000 shares at $13.88 per share price.On Jul 8, 2015, Daniel Philip Gottlieb (VP Marketing & Bus Development) sold 1,965 shares at $16.86 per share price, according to the Form-4 filing with the securities and exchange commission.

Proteon Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is primarily involved in research and development activities. The Company’s product candidate PRT-201 is a recombinant human elastase that it is developing to reduce vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of PRT-201 in patients undergoing creation of an arteriovenous fistula (AVF). It initiated the first of two Phase III trials for PRT-201 in radiocephalic AVFs.

Add Comment